Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a clinical-stage regenerative medicine company that completed its de-SPAC merger with Alpha Healthcare Acquisition Corp., sponsored by Alpha Healthcare Holdings LLC, in August 2021, gaining a public listing on Nasdaq. The blank-check vehicle, which conducted its IPO in 2020, focused on the biotechnology and medical technology sectors before selecting Humacyte as its combination target. The company develops bioengineered human acellular vessels intended for vascular repair and reconstruction across multiple surgical indications. The Form 10-Q filed August 16, 2021 reflects one of Humacyte's first reporting periods as a newly public entity. Sign up at SpacDesk for full data on HUMA, including deal timelines, filing history, and sector comparables.